Cummins Katherine, Gill Saar
Peter MacCallum Cancer Centre, University of Melbourne, 305 Grattan Street, Melbourne, VIC 3000, Australia.
Division of Hematology-Oncology, University of Pennsylvania Perelman School of Medicine, 8-101 Smilow Center for Translational Research, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA.
Hematol Oncol Clin North Am. 2023 Dec;37(6):1125-1147. doi: 10.1016/j.hoc.2023.06.004. Epub 2023 Jul 11.
Up to 30% of patients with acute myeloid leukemia (AML) who undergo chimeric antigen receptor (CAR) T-cell therapy have evidence of response, although trials are highly heterogeneous. These responses are rarely deep or durable. CD123, CD33, and CLL-1 have emerged as the most common targets for CAR T cells in AML. CAR T cells against myeloid antigens cause myeloablation as well as cytokine release syndrome, although neurotoxicity is rarely seen. Future efforts should focus on AML-specific antigen discovery or engineering, and on further enhancing the activity of CAR T cells.
高达30%接受嵌合抗原受体（CAR）T细胞疗法的急性髓系白血病（AML）患者有反应迹象，尽管试验具有高度异质性。这些反应很少是深度或持久的。CD123、CD33和CLL-1已成为AML中CAR T细胞最常见的靶点。针对髓系抗原的CAR T细胞会导致骨髓消融以及细胞因子释放综合征，尽管很少见神经毒性。未来的工作应集中在AML特异性抗原的发现或工程改造，以及进一步增强CAR T细胞的活性。
